Cue Biopharma, Inc. Underwriting Agreement and Public Offering

On December 19, 2025, Cue Biopharma, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC for an underwritten public offering. The offering includes 12,500,000 shares of common stock and accompanying warrants, as well as pre-funded warrants to purchase additional shares. The combined offering price for a share of common stock and a warrant is $0.28, and for a pre-funded warrant and a warrant is $0.279. The company granted the underwriters an option to purchase additional shares and warrants. Cue Biopharma estimates net proceeds of approximately $8.9 million, or $10.3 million if the option is fully exercised, after deducting underwriting discounts and commissions, and estimated offering expenses. These proceeds, along with existing capital and collaboration payments, are expected to fund operations into the first quarter of 2027. The offering is expected to close around December 22, 2025. The company also noted that its common stock is listed on the Nasdaq Capital Market under the symbol CUE and is working to comply with listing requirements.